NORTHERN-DATA-AG
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the world's largest providers of high-performance computing (HPC) solutions, today reports that the Corona Virus / COVID-19 -Pandemic is resulting in a massive increase in computing capacity demand. In order to meet the increased demand, the company has instigated an acceleration of the expansion of capacities at its locations and in addition is looking to develop further locations.
Immediate demand for computing power in the wake of the pandemic is being driven by two immediate and game changing developments: Firstly, pharmaceutical companies and research institutions worldwide are using HPC systems on a large scale for the first time in order to carry out calculations and simulations in the field of bioinformatics and epidemiology in the shortest possible time, which with conventional computer systems can take several months or even years. This gives research teams the opportunity to accelerate the development of novel drugs that can be used against the coronavirus in the short term. Northern Data management expects this trend to continue after the end of the COVID 19 pandemic.
Secondly working conditions worldwide have shifted drastically online in a matter of weeks through the course of the COVID 19 pandemic, this has led to a massive increase in demand for computing capacity. Due to the current restrictions, many companies in parts of the United States, Europe and Asia are forced to operate with an almost 100% home office ratio. The associated use of digital applications such as video conferencing tools is causing an explosion in demand for data capacities. Also, this trend will continue beyond the corona crisis.
Northern Data will start operating its newest HPC facility in the United States in the coming days. The world's largest HPC data center is being built in Texas on an area of more than 100 acres, which corresponds to the size of around 57 soccer fields. The company originally intended to achieve a total capacity of one gigawatt at the US location by the end of the year. Due to the changed and overwhelming demand situation, plans are now beginning to seamlessly expand the location to up to 3.6 gigawatts.
The company is also accelerating the development of additional locations for additional large-scale HPC facilities in Canada and Scandinavia.
"We are facing overwhelming demand," said Aroosh Thillainathan, CEO of Northern Data AG. "In some areas we see a thirty times higher market demand than we can build up capacities by the end of the year. We now benefit from our many years of experience in large-scale high-performance computing in order to further accelerate ongoing scaling."
Northern Data published its forecast for 2020 on March 16. Based on current expectations and in line with contracts already signed, the Management Board expects revenues of EUR 120 million to EUR 140 million in the course of 2020. Accordingly, the Management Board expects EBITDA of between EUR 45 million and EUR 60 million. This guidance is based only on a partial utilization of initially 30% of the 1GW expansion stage, based on already concluded contracts for the provision of HPC solutions with global customers. The forecast will be adjusted in due course as new customer acquisition progresses.
About Northern Data:
Northern Data AG develops and builds global infrastructure solutions in the area of high-performance computing (HPC). The company offers solutions in areas such as machine learning and artificial intelligence, big data analytics, blockchain, game streaming and others. The international company emerged from the merger of the German Northern Bitcoin AG and the American Whinstone US, Inc. and is today a recognized market leader in the field of HPC solutions worldwide. Northern Data offers its HPC solutions both stationary in large, state-of-the-art data centers and in mobile, high-tech data centers based on containers, which can be set up at any location worldwide. It combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. In Texas, Whinstone is currently building the largest HPC data center in the United States and the largest facility in the world specifically for HPC applications.
| Language: | English |
| Company: | Northern Data AG |
| Thurn-und-Taxis-Platz 6 | |
| 60313 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northerndata.de |
| Internet: | www.northerndata.de |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate |
| Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200329005043/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
